Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Other Non-Current Liabilities (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Other Non-Current Liabilities data on record, last reported at $38.4 million in Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities changed N/A year-over-year to $38.4 million; the TTM value through Jun 2025 reached $38.4 million, changed N/A, while the annual FY2024 figure was $44.4 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $38.4 million in Q2 2025 per CAI's latest filing, down from $44.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $44.4 million in Q4 2024 and bottomed at $38.4 million in Q2 2025.